California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...

Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead ...

Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

Soaring demand for weight-loss drugs, expected to be a $150 billion market by early 2030s, has attracted more investors toward companies tapping into the lucrative market. The debut valued BioAge at ...

Obesity-drug developer BioAge Labs Inc. gained about 20% after its initial public offering on Thursday, while natural-gas producer BKV Inc. was up fractionally over its $18 IPO price. BioAge (BIOA) ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, visits the Nasdaq ...

BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity ...

Texas-based Barnett Shale driller BKV Inc. priced below the estimated range, while obesity-drug developer BioAge Labs Inc. priced midrange ahead of their first day of trading on Thursday. As the ...